Principal Financial Group Inc. Increases Stock Holdings in TransMedics Group, Inc. $TMDX

Posted by George Bondi on Jul 21st, 2026

Principal Financial Group Inc. boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 19.4% in the first quarter, HoldingsChannel reports. The institutional investor owned 231,433 shares of the company’s stock after buying an additional 37,656 shares during the quarter. Principal Financial Group Inc.’s holdings in TransMedics Group were worth $23,007,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TMDX. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group during the 3rd quarter worth $29,000. Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors bought a new position in shares of TransMedics Group during the first quarter valued at about $30,000. Finally, North Star Investment Management Corp. bought a new position in shares of TransMedics Group during the first quarter valued at about $30,000. 99.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TMDX shares. Piper Sandler reduced their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Needham & Company LLC dropped their target price on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Finally, Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of “Hold” and a consensus price target of $134.50.

Check Out Our Latest Research Report on TMDX

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $73.47 on Tuesday. The company’s 50-day moving average is $71.02 and its 200 day moving average is $104.11. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The company has a market capitalization of $2.54 billion, a P/E ratio of 16.70 and a beta of 1.89. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the previous year, the company posted $0.70 EPS. TransMedics Group’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1.92 earnings per share for the current year.

About TransMedics Group

(Free Report)

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).

Institutional Ownership by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.